Progen Appoints New Chief Executive Officer
Brisbane, Australia, 29
March 2010. The Directors of Progen Pharmaceuticals (ASX: PGL, NASDAQ:
PGLA) are delighted to announce the appointment of Sue MacLeman as Chief Executive Officer.
Sue MacLeman has extensive international senior management and leadership experience in product development
and commercialisation in the biotechnology and pharmaceutical sector.
Sue graduated with a Bachelor of Pharmacy from the University of Queensland in 1984. In addition to pharmacy
qualifications, Sue MacLeman has completed a Masters of Marketing degree at Melbourne University
(Melbourne Business School) , a Masters of Commercial Law degree (Deakin University) and a Fellowship with
the Australian College of Pharmacy Practice. She is also a Fellow of the Australian Institute of Company
Directors. Sue is also a member of the Pharmaceutical Industry Council (PIC) and Pharmaceutical Industry
Working Group (PIWG) and the Chair of the Pharmaceutical Industry Development Taskforce (PIDT).
In 1991 Sue joined the pharmaceutical industry with Schering Plough in the biotechnology business unit. She then
went on to work with Amgen Inc and Bristol Myers Squibb Pharmaceuticals in the areas of oncology and
infectious diseases medical, marketing, sales management and business development. In 2002 Sue took up the
position of global Vice President for Agenix Ltd where she was responsible for the product development of the
molecular clot imaging project. From 2004 to 2006 she was the CEO of publicly listed biotechnology investment
and management company EQiTX Ltd. Most recently Sue was CEO of RNAi therapeutics company Benitec
“The appointment of Sue MacLeman is an important milestone in the strategic development of Progen
Pharmaceuticals. Sue brings a wealth of oncology experience and an impressive track record of product
development and commercialisation in the biotechnology sector.Sue’s appointment will greatly strengthen t